PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics, Inc. announces that two key manuscripts on the ChemoFx® drug response marker have been accepted for publication. British Journal of Cancer, the elite professional medical journal of Cancer Research UK, has accepted a manuscript detailing the predictive abilities of ChemoFx. In addition, Clinical and Translational Oncology has accepted a manuscript that examines whether access to ChemoFx results has a positive impact on patient outcomes. Together, these key publications will provide further evidence of the clinical utility of the drug response marker as well as answer important clinical questions asked by physicians personalizing patient treatment and payers covering this important test.
The first manuscript, Evaluation of a Chemoresponse Assay as a Predictive Marker in the Treatment of Recurrent Ovarian Cancer: Further Analysis of a Prospective Study, utilizes four separate statistical analyses to examine whether ChemoFx is able to identify specific sensitive treatments for ovarian cancer patients. The identified chemotherapies could potentially be more effective for the individual patient. Initial findings were presented at the 2013 European Cancer Congress Annual Meeting.
The second manuscript, Overview of a Chemoresponse Assay in Ovarian Cancer, is the full publication of an abstract presented at the 2013 AACR Meeting - Advances in Ovarian Cancer Research: From Concept to Clinic. This manuscript releases a comparative analysis conducted between a Herzog, 2010 study and four previously accrued and published National Cancer Institute (NCI) funded cooperative group drug studies in advanced epithelial ovarian cancer. The publication examines whether patients treated by physicians with access to assay results experience improved outcomes when compared to patients treated by physicians without access to ChemoFx results.
“The implications of these findings are pivotal to the gynecologic cancer community, particularly for women at high risk, for survivors fighting the disease and for those facing recurrence,” said Arlette H. Uihlein, MD, Medical Director of Precision Therapeutics. “A study showing that ChemoFx can not only predict how a patient will respond to treatment, but also to which treatment that patient will benefit, has the potential to change treatment paradigms.”
ChemoFx is a proprietary drug response marker which quantifies an individual gynecologic cancer patient’s probable tumor response to a range of standard chemotherapeutic options. ChemoFx has been validated in previously conducted clinical studies, with data demonstrating a 14-month improvement in overall survival and 50% increase in progression-free survival when recurrent ovarian cancer patients are treated with ‘responsive’ therapies as indicated by ChemoFx.
About Ovarian Cancer:
More than 22,000 women in the United States are newly-diagnosed with ovarian cancer each year. Approximately 80% of all women with ovarian cancer have their disease recur, and 20-30% of recurrences occur within 6 months of the end of first-line therapy. The majority of patients with ovarian cancer (more than 70%), present with advanced disease at initial diagnosis, and women with advanced ovarian cancer tend to have multiple relapses and undergo several rounds of chemotherapy. There have been modest gains in ovarian cancer statistics in the last two decades, with only a small percentage of improvement in overall survival rates for recurrent ovarian cancer.
About Precision Therapeutics:
Precision Therapeutics, Inc., a life-science company located in Pittsburgh, PA, is dedicated to personalizing cancer care and improving patient outcomes. As leaders in the science of individualizing cancer therapy, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual’s cancer. In addition to ChemoFx, Precision also offers BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis. For more information, visit: www.precisiontherapeutics.com or www.chemofx.com.